Acadia Pharmaceuticals (ACAD) Research & Development (2010 - 2026)

Acadia Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $76.9 million for Q1 2026.

• In Q1 2026, Research & Development fell 1.78% year-over-year to $76.9 million; the TTM figure through Mar 2026 stood at $327.4 million (up 1.73% YoY), while the FY2025 annual figure was $328.8 million, up 8.43% from the prior year.
• Research & Development was $76.9 million for Q1 2026 at Acadia Pharmaceuticals, down from $84.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $157.0 million in Q3 2023 to a low of $58.8 million in Q2 2023.
• Historically, Research & Development has averaged $83.7 million across 5 years, with a median of $76.9 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 126.17% in 2022, then slumped 57.57% in 2024.
• A 5-year view of Research & Development shows it stood at $75.7 million in 2022, then slipped by 11.88% to $66.7 million in 2023, then jumped by 50.93% to $100.7 million in 2024, then retreated by 15.86% to $84.8 million in 2025, then slipped by 9.31% to $76.9 million in 2026.
• The last three Research & Development figures came in at $76.9 million (Q1 2026), $84.8 million (Q4 2025), and $87.8 million (Q3 2025), per Business Quant data.